Category Archives: Companies

Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

covid 19

March 17, 2020 – Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic. 

Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging emergency results. Vitro Biopharma has the highest level of umbilical cord stem cell technology to reduce death rates due to the Coronavirus pandemic.

https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese- patient-saved-stem-cell

https://www.dailytargum.com/article/2020/03/commentary-compassionate-use-of-stem-cell- therapy-to-treat-severe-covid-19-could-save-lives-now

http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml

Dr. Jim Musick, Ph.D., CEO said, “As the world struggles to deal with the COVID-19 pandemic, it is important to consider stem cell therapy to reduce death rates. This is supported by clinical studies and clinical trials are underway to substantiate safety and efficacy. Vitro Biopharma is ideally suited to provide high quality stem cells to US patients, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our umbilical cord AlloRx™ Stem Cells and stem cell growth media MSC-Gro™ have been used in the treatment of hundreds of patients without adverse events and show efficacy in treatment of COPD, osteoarthritis, multiple sclerosis and Alzheimer’s disease.

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx™ Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands www.DVCStem.com.

Vitro Biopharma has a patent-pending, proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients. Our stem cells have been shown to be safe in Phase I protocols as we also gain evidence of efficacy.

We are in contact with federal, state and local governments to inform them of our AlloRx ™ Stem Cell therapy option for Coronavirus infections.. The pandemic deserves consideration of all therapeutic options and there is evidence that stem cell therapy reduces the death rate from Coronavirus COVID-19 infections. We believe that critically ill patients should have the right to try stem cell therapy in the United States.”

CONTACT:
Dr. James Musick Chief Executive Officer
Vitro Biopharma (303) 550-2778
E-mail: jim@vitrobiopharma.com
Source: Vitro Diagnostics, Inc

Forward-Looking Statements
Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,”
“anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.

Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.

Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

MRI Interventions Reports 52% Increase in First Quarter Revenue

MRI Interventions logo

Record $2.5 million quarterly revenue driven by growth across entire portfolio OTCQB: MRIC) (the “Company”) today announced financial results for its first fiscal quarter ended March 31, 2019.

First Quarter 2019 Highlights

  • Increased first quarter revenue 52% year-over-year to $2.5 million.
  • Reported $1.6 million in quarterly functional neurosurgery revenue, an increase of 38% over the prior year first quarter.
  • Reported biologics and drug delivery revenue of $382,000, an increase of 93% over the prior year, including first European shipments to Lysogene for use in their P4-SAF-302 trial.
  • Reported capital sales and other services revenue of $486,000, which includes two system sales; the systems sales, combined with three evaluation installations, bring total U.S. installed base to 63 systems.
  • Completed 175 procedures across the Company’s product portfolio.
  • Completed the transfer of the V-Tag 510(k) from Voyager Therapeutics, Inc. and completed initial clinical builds.
  • Generated gross margin of 64%.
  • Maintained reduction of cash used in operations to $609,000, which included annual bonus compensation and semi-annual interest payment.

Leatt Corp Announces Record Breaking Year; Reports Results for Fourth Quarter and Full Year 2018

Leatt logo

21% Increase in Revenues to $24.4 million; 404% Increase in Net Income to $1.2 million

Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of protective equipment and ancillary products for many forms of sports, especially extreme high-velocity sports, today announced record financial results for the fourth quarter and full year ending December 31, 2018. All financial numbers are in U.S. dollars.

Mikros Systems Corporation Reports 2017 Financial Results

Mikros Systems Corporation (OTCQB:MKRS), an advanced technology company specializing in electronic systems technology for advanced maintenance in military, industrial and commercial applications, today announced financial results for 2017.

Revenues for 2017 were $7,196,131 compared to $5,067,365 in 2016, an increase of $2,128,766, or 42%. The increase was due primarily to production orders for 37 Adaptive Diagnostic Electronic Portable Testset (ADEPT) units in 2017 and the receipt of additional contract awards and task orders for engineering services, support, repairs and calibration services.

Icynene To Acquire Lapolla Industries For $1.03 Per Share In All Cash Transaction

icynene

Strategic Combination to Create Industry-Leading Manufacturer and Distributor of Performance Spray Foam Insulation

MISSISSAUGA, Ontario and HOUSTONOct. 5, 2017 /PRNewswire/ — Icynene U.S. Holding Corp. (“Icynene”) and Lapolla Industries Inc. (“Lapolla”) (LPAD) today announced that they have entered into a definitive merger agreement under which Icynene will acquire all the outstanding shares of Lapolla.  The transaction is valued at approximately $160 million, including net debt.

Under the terms of the agreement, stockholders of Lapolla will receive $1.03 in cash for each share of Lapolla that they own.  The transaction was unanimously approved by Lapolla’s board of directors and, following Lapolla’s entry into the agreement, Lapolla stockholders holding approximately 78% of Lapolla’s issued and outstanding voting shares executed a written consent approving the merger agreement and the transaction.